Published on: 22nd March 2024

We are delighted to announce that Michael Macdonnell will join the RNOH Trust Board as a Non-Executive Director from 1 April 2024. He brings extensive experience from his long and established career within the UK and worldwide healthcare industries and will be a welcome addition to our existing board expertise as RNOH develops and grows its specialist services in the years ahead.

Michael Macdonnell resized.pngMichael is currently Global Head of Healthcare and Pharma Partnerships at Huma Therapeutics, a UK-based technology company dedicated to digital-first care and research. Previously, Michael was Director of Partnerships and Deployment for DeepMind, a British-American artificial intelligence research laboratory, and then for Google Health, working in the UK and internationally. He was also Director of Strategy for NHS England, then National Director of System Transformation. 

Michael said: “I’m delighted to join RNOH - the NHS’s leading specialist orthopaedic hospital, and one with a growing international reputation too. Musculoskeletal conditions affect millions of people across the country, preventing them from leading full, disability-free and productive lives. I’m proud to join the team of a hospital that can impact so many people in London and beyond.”

Upon joining the board in April, Michael will chair the Finance and Compliance Committee.

RNOH Chair, Doris Olulode, said: “On behalf of RNOH, I am pleased to welcome Michael to the Trust Board. He brings a wealth of experience and expertise within the field of healthcare and I look forward to working closely with him as we navigate the opportunities and challenges ahead.”